Developer docs
API playgroundTry for free, no card

Search company profiles

Woebot Health

Full company profile

uuid00005ke

Namestring
Woebot Health
Legal namestring
Woebot Health
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Woebot Health is a San Francisco-based digital mental health company founded in 2017 by clinical research psychologist Dr. Alison Darcy. The company builds a chat-based AI platform that delivers evidence-based therapeutic techniques rooted in Cognitive Behavioral Therapy, Dialectical Behavior Therapy, and Interpersonal Psychotherapy. Its product portfolio includes Woebot for Adults, Woebot for Adolescents (ages 13-17), Woebot for Maternal Health, and Woebot for Adults 65+, supported by B2B modules such as Access Accelerator (clinician-facing EMR integration with patient-reported outcomes capture), Population Health (payer insights), and a Medicare Advantage solution. The underlying technology combines proprietary NLP for concerning language detection with LLM-based input classification that routes users to human-composed, clinically overseen content; generative LLM capabilities are deployed only in IRB-regulated research settings. Woebot's evidence base spans 18+ randomized controlled trials, and the platform holds FDA Breakthrough Device designation, HIPAA and GDPR compliance, and ORCHA certification, though none of its products are FDA-cleared.

Woebot pivoted in June 2025 from a direct-to-consumer subscription model ($39-$49 per month) to a B2B licensing model following a shutdown of its consumer app after serving over 1.5 million users. Revenue is now generated by licensing the platform to healthcare providers, payers, and employers through enterprise contracts, with named health system customers including Akron Children's Hospital, Virtua Health, ChristianaCare, and Hackensack Meridian Health. Distribution is primarily through healthcare provider recommendations, payer and employer wellness programs, and EMR integrations rather than direct consumer acquisition. The company has raised over $123.5 million in total funding across rounds including a $90 million Series B (July 2021, led by Jazz Venture Partners and Temasek) and a $9.5 million strategic investment from Bayer's impact investing arm (March 2022), with a headcount of 51-100 employees.

Short descriptiontext

Woebot Health is a San Francisco-based digital mental health company that licenses a chat-based AI platform delivering CBT, DBT, and IPT-based therapeutic support to healthcare providers, payers, and employers serving adults, adolescents, maternal, and senior populations.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
digital mental health, AI therapy chatbot, behavioral health platform, cognitive behavioral therapy, digital therapeutics
Industry4 codes
1Medication Adherence, Digital Therapeutics & Remote Coaching (condition-specific programs)
CodeHLALAFAFPrimaryYes
2Health Information Exchange & Public Health Data Integration
CodeHLAJAJADPrimaryNo
3HIE Platforms & Network Services (Community/Regional/National)
CodeHLACABABPrimaryNo
4Interoperability Standards, Profiles & Implementation (HL7/FHIR/IHE)
CodeHLACABAAPrimaryNo
NAICS code1 code
  • Outpatient Mental Health and Substance Abuse Centers621420
SIC code1 code
  • Services-Prepackaged Software7372
Product category
Digital Mental Health
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1B2B Platform Licensing
TypeSubscription Recurring
Description

Woebot Health generates revenue by licensing its platform to healthcare providers (health systems, clinics), payers (insurance companies), and employers. The platform is offered as a white-label or branded solution integrated into existing care pathways and employee wellness programs.

skywork.ai
2Historical Direct-to-Consumer Subscription
TypeSubscription Recurring
Description

Prior to the June 2025 shutdown, Woebot offered subscription pricing at $39-$49 per month directly to consumers. This model was discontinued due to FDA regulatory costs and the rise of LLMs making the rule-based approach feel outdated.

oreateai.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Former Direct-to-Consumer Premium
ModelSubscriptionBilling cadenceMonthly
Notes

$39 to $49 per month. Provided 24/7 AI-powered mental health support with CBT-based techniques, mood tracking, and mindfulness practice. Discontinued as of June 30, 2025.

oreateai.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Woebot Health provides a chat-based AI mental health platform delivering evidence-based therapeutic techniques (CBT, DBT, IPT) to users as an adjunct to clinical care. Following its June 2025 pivot to a B2B model, the company licenses its platform to healthcare providers, payers, and employers, offering population-specific products (Woebot for Adults, Adolescents, Maternal Health, and Adults 65+) along with B2B solutions (Access Accelerator, Population Health, Medicare Advantage Solution).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Over 1.5 million users served before direct-to-consumer shutdown
+1 more record
Product overview1 text field

Woebot Health is an AI-powered digital mental health company offering a suite of chat-based wellness tools. The core offering is the Woebot Health Platform, a foundational development platform that powers multiple product variants. The portfolio includes Woebot for Adults, Woebot for Adolescents, Woebot for Maternal Health, and Woebot for Adults 65+ — each population-specific product built on the shared platform. B2B solutions include Access Accelerator for clinicians (with EMR integration and PRO data collection), Population Health tools for payers and employers, and Medicare Advantage solutions. The company pivoted from direct-to-consumer to B2B in 2025, with products now offered primarily through healthcare providers, employers, and insurers. None of the products are FDA-cleared; all are positioned as adjuncts to clinical care.

Product and service2 records
1Woebot Health Platform
Categoryplatform
Description

The foundational development platform that powers multiple Woebot mental health products across different regulatory guidances. Provides AI-driven conversational capabilities used to build population-specific digital therapeutic solutions for healthcare providers, payers, and employers.

2Woebot for Adults
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-08-21
Description

Woebot Health partnered with Akron Children's Hospital to provide Woebot for Adolescents (ages 13-17) as a free mental health support tool for teen patients. The partnership addresses the mental health provider shortage for adolescents.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Virtua Health partnered with Woebot Health to offer Woebot for Adults to patients, featuring the app in 60 Minutes coverage and NJ Spotlight News reports.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

ChristianaCare partnered with Woebot Health to provide provider training and deployment of Woebot for Adults for their patient population.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Hackensack Meridian Health partnered with Woebot Health to provide provider training and deployment of Woebot for Adults for their patient population.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Consumer and enterprise mental wellness platform with meditation, sleep, and now employer mental health benefits. Broader and less clinically specialized than Woebot but competes for the same employer wellness dollar.

TypeDirect peer
Description

AI-driven chat-based mental health chatbot delivering CBT-based support to consumers, payers, and employers. Most direct competitor in the conversational mental health AI category, serving similar populations including adolescents and workplace mental health.

TypeBroad incumbent
Description

Large-scale mental health platform combining consumer content, meditation, and therapy services (including the Ginger acquisition). Competes with Woebot in employer, payer, and health system channels with a broader, less AI-specialized offering.

TypeDirect peer
Description

Mental health benefits platform for employers and payers combining provider matching, live therapy, and digital self-service. Targets the same payer/employer buyer as Woebot's B2B motion and includes digital coaching tools analogous to Woebot.

TypeDirect peer
Description

Employer- and payer-facing mental health benefits platform offering assessments, digital exercises, and provider matching. Competes with Woebot for the same employer wellness and payer population health budgets.

TypeDirect peer
Description

Online therapy platform serving payers, employers, and individuals via text/audio/video with therapists. Comparable B2B2C model and overlap in payer and employer distribution channels, though primarily human-delivered rather than AI-led.

TypeDirect peer
Description

Conversational AI mental health chatbot delivering CBT, DBT, and psychoeducation via chat, with health system and employer deployments. Closest technology analog to Woebot's rule-based, human-authored CBT dialogue approach.

TypeEmerging player
Description

Digital therapeutic company focused on insomnia and anxiety, with FDA-cleared assets and enterprise distribution through payers and employers. Competes for similar digital therapeutic budgets and demonstrates the FDA-cleared DTx path Woebot has not pursued.

TypeEmerging player
Description

Online mental health provider offering therapy and medication management with an emphasis on anxiety and depression treatment. Targets similar patient populations and has overlapping payer relationships, though delivery is clinician-led rather than AI-first.

TypeEmerging player
Description

Digital mental health clinic combining clinician-led care with digital therapeutic exercises, sold to payers and employers. Comparable B2B digital therapeutic model and population health orientation.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Woebot Health

Digital Mental Healthwoebothealth.com

Woebot Health is a San Francisco-based digital mental health company that licenses a chat-based AI platform delivering CBT, DBT, and IPT-based therapeutic support to healthcare providers, payers, and employers serving adults, adolescents, maternal, and senior populations.

What Woebot Health does

Woebot Health is a San Francisco-based digital mental health company founded in 2017 by clinical research psychologist Dr. Alison Darcy. The company builds a chat-based AI platform that delivers evidence-based therapeutic techniques rooted in Cognitive Behavioral Therapy, Dialectical Behavior Therapy, and Interpersonal Psychotherapy. Its product portfolio includes Woebot for Adults, Woebot for Adolescents (ages 13-17), Woebot for Maternal Health, and Woebot for Adults 65+, supported by B2B modules such as Access Accelerator (clinician-facing EMR integration with patient-reported outcomes capture), Population Health (payer insights), and a Medicare Advantage solution. The underlying technology combines proprietary NLP for concerning language detection with LLM-based input classification that routes users to human-composed, clinically overseen content; generative LLM capabilities are deployed only in IRB-regulated research settings. Woebot's evidence base spans 18+ randomized controlled trials, and the platform holds FDA Breakthrough Device designation, HIPAA and GDPR compliance, and ORCHA certification, though none of its products are FDA-cleared.

Woebot pivoted in June 2025 from a direct-to-consumer subscription model ($39-$49 per month) to a B2B licensing model following a shutdown of its consumer app after serving over 1.5 million users. Revenue is now generated by licensing the platform to healthcare providers, payers, and employers through enterprise contracts, with named health system customers including Akron Children's Hospital, Virtua Health, ChristianaCare, and Hackensack Meridian Health. Distribution is primarily through healthcare provider recommendations, payer and employer wellness programs, and EMR integrations rather than direct consumer acquisition. The company has raised over $123.5 million in total funding across rounds including a $90 million Series B (July 2021, led by Jazz Venture Partners and Temasek) and a $9.5 million strategic investment from Bayer's impact investing arm (March 2022), with a headcount of 51-100 employees.

Woebot Health firmographics

Firmographics
Name
Woebot Health
Legal name
Woebot Health
Website
https://woebothealth.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
51–100 employees
Short description
Woebot Health is a San Francisco-based digital mental health company that licenses a chat-based AI platform delivering CBT, DBT, and IPT-based therapeutic support to healthcare providers, payers, and employers serving adults, adolescents, maternal, and senior populations.
Ownership category
akta.pro rank

Woebot Health industry classification

Industry
Product category
Digital Mental Health
NAICS
Outpatient Mental Health and Substance Abuse Centers (621420)
SIC
Services-Prepackaged Software (7372)
akta.pro primary industry
Medication Adherence, Digital Therapeutics & Remote Coaching (condition-specific programs) (HLALAFAF)
akta.pro secondary industries
Health Information Exchange & Public Health Data Integration (HLAJAJAD), HIE Platforms & Network Services (Community/Regional/National) (HLACABAB), Interoperability Standards, Profiles & Implementation (HL7/FHIR/IHE) (HLACABAA)

Keywords

  • Digital mental health
  • AI therapy chatbot
  • Behavioral health platform
  • Cognitive behavioral therapy
  • Digital therapeutics

Where Woebot Health is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Woebot Health business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. B2B Platform Licensing: Woebot Health generates revenue by licensing its platform to healthcare providers (health systems, clinics), payers (insurance companies), and employers. The platform is offered as a white-label or branded solution integrated into existing care pathways and employee wellness programs.
  2. Historical Direct-to-Consumer Subscription: Prior to the June 2025 shutdown, Woebot offered subscription pricing at $39-$49 per month directly to consumers. This model was discontinued due to FDA regulatory costs and the rise of LLMs making the rule-based approach feel outdated.

Pricing tiers

ModelBillingPrice
SubscriptionMonthlyFormer Direct-to-Consumer Premium

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Woebot Health product offering

Product offering

Core offering

Woebot Health provides a chat-based AI mental health platform delivering evidence-based therapeutic techniques (CBT, DBT, IPT) to users as an adjunct to clinical care. Following its June 2025 pivot to a B2B model, the company licenses its platform to healthcare providers, payers, and employers, offering population-specific products (Woebot for Adults, Adolescents, Maternal Health, and Adults 65+) along with B2B solutions (Access Accelerator, Population Health, Medicare Advantage Solution).

Product overview

Woebot Health is an AI-powered digital mental health company offering a suite of chat-based wellness tools. The core offering is the Woebot Health Platform, a foundational development platform that powers multiple product variants. The portfolio includes Woebot for Adults, Woebot for Adolescents, Woebot for Maternal Health, and Woebot for Adults 65+ — each population-specific product built on the shared platform. B2B solutions include Access Accelerator for clinicians (with EMR integration and PRO data collection), Population Health tools for payers and employers, and Medicare Advantage solutions. The company pivoted from direct-to-consumer to B2B in 2025, with products now offered primarily through healthcare providers, employers, and insurers. None of the products are FDA-cleared; all are positioned as adjuncts to clinical care.

Differentiator

Problem solved

Functional benefit

Products and services

  • Woebot Health Platform The foundational development platform that powers multiple Woebot mental health products across different regulatory guidances. Provides AI-driven conversational capabilities used to build population-specific digital therapeutic solutions for healthcare providers, payers, and employers.
  • Woebot for Adults

Quantifiable outcome

  • Over 1.5 million users served before direct-to-consumer shutdown
  • +1 more outcomes

Companies that use Woebot Health

Customer profile

Named customers4 records

Segments5 records

Ideal customer profiles3 records

Woebot Health technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability4 records

Feature4 records

Woebot Health partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • Akron Children's HospitalcoreStrategic or Co-development Partner · 21 August 2024Woebot Health partnered with Akron Children's Hospital to provide Woebot for Adolescents (ages 13-17) as a free mental health support tool for teen patients. The partnership addresses the mental health provider shortage for adolescents.
  • Virtua HealthcoreStrategic or Co-development PartnerVirtua Health partnered with Woebot Health to offer Woebot for Adults to patients, featuring the app in 60 Minutes coverage and NJ Spotlight News reports.
  • ChristianaCarecoreStrategic or Co-development PartnerChristianaCare partnered with Woebot Health to provide provider training and deployment of Woebot for Adults for their patient population.
  • Hackensack Meridian HealthcoreStrategic or Co-development PartnerHackensack Meridian Health partnered with Woebot Health to provide provider training and deployment of Woebot for Adults for their patient population.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Woebot Health competitors and assessment

Company assessment

Broad incumbents

  • Calm Health: Consumer and enterprise mental wellness platform with meditation, sleep, and now employer mental health benefits. Broader and less clinically specialized than Woebot but competes for the same employer wellness dollar.
  • Headspace Health: Large-scale mental health platform combining consumer content, meditation, and therapy services (including the Ginger acquisition). Competes with Woebot in employer, payer, and health system channels with a broader, less AI-specialized offering.

Direct peers

  • Wysa: AI-driven chat-based mental health chatbot delivering CBT-based support to consumers, payers, and employers. Most direct competitor in the conversational mental health AI category, serving similar populations including adolescents and workplace mental health.
  • Lyra Health: Mental health benefits platform for employers and payers combining provider matching, live therapy, and digital self-service. Targets the same payer/employer buyer as Woebot's B2B motion and includes digital coaching tools analogous to Woebot.
  • Spring Health: Employer- and payer-facing mental health benefits platform offering assessments, digital exercises, and provider matching. Competes with Woebot for the same employer wellness and payer population health budgets.
  • Talkspace: Online therapy platform serving payers, employers, and individuals via text/audio/video with therapists. Comparable B2B2C model and overlap in payer and employer distribution channels, though primarily human-delivered rather than AI-led.
  • Tess (X2AI): Conversational AI mental health chatbot delivering CBT, DBT, and psychoeducation via chat, with health system and employer deployments. Closest technology analog to Woebot's rule-based, human-authored CBT dialogue approach.

Emerging players

  • Big Health (Sleepio): Digital therapeutic company focused on insomnia and anxiety, with FDA-cleared assets and enterprise distribution through payers and employers. Competes for similar digital therapeutic budgets and demonstrates the FDA-cleared DTx path Woebot has not pursued.
  • Cerebral: Online mental health provider offering therapy and medication management with an emphasis on anxiety and depression treatment. Targets similar patient populations and has overlapping payer relationships, though delivery is clinician-led rather than AI-first.
  • Meru Health: Digital mental health clinic combining clinician-led care with digital therapeutic exercises, sold to payers and employers. Comparable B2B digital therapeutic model and population health orientation.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Woebot Health social profiles

Digital presence

Woebot Health compliance and trust

Trust signal

Compliance2 records

Woebot Health financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Woebot Health leadership team

Management profile

Number of profiles

Profiles15 records

Woebot Health funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Woebot Health M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Woebot Health

What does Woebot Health do?

Woebot Health provides a chat-based AI mental health platform delivering evidence-based therapeutic techniques (CBT, DBT, IPT) to users as an adjunct to clinical care. Following its June 2025 pivot to a B2B model, the company licenses its platform to healthcare providers, payers, and employers, offering population-specific products (Woebot for Adults, Adolescents, Maternal Health, and Adults 65+) along with B2B solutions (Access Accelerator, Population Health, Medicare Advantage Solution).

Is Woebot Health a public or private company?

Woebot Health is a private company. It is classified as venture growth investor backed and is currently operating.

When was Woebot Health founded?

Woebot Health was founded in 2017. It employs 51 to 100 people.

Where is Woebot Health based?

Woebot Health is headquartered in San Francisco, United States, in the North America region.

How does Woebot Health make money?

Two revenue lines are on record. B2B Platform Licensing is the primary driver. The others are historical Direct-to-Consumer Subscription.

Who are Woebot Health's main competitors?

Broad incumbents on record are Calm Health and Headspace Health. Direct peers are Wysa, Lyra Health, Spring Health, Talkspace and Tess (X2AI). Emerging players are Big Health (Sleepio), Cerebral and Meru Health.

Does Woebot Health have an API?

No public API is recorded for Woebot Health.

What industry is Woebot Health in?

Woebot Health's product category is Digital Mental Health. Its primary akta.pro industry code is HLALAFAF, Medication Adherence, Digital Therapeutics & Remote Coaching (condition-specific programs), with a secondary code of HLAJAJAD, Health Information Exchange & Public Health Data Integration. Its NAICS code is 621420 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
pharmaphorumDigital mental health specialist Woebot raises $90mWoebot raised $90 million in a round co-led by JAZZ Venture Partners and Temasek, bringing its total funding to $114 million. The California startup will use the funds to develop its CBT-based digital therapeutics and expand its workforce. The financing follows an FDA breakthrough designation for WB001, a smartphone-based treatment for postpartum depression.Santa Clara UniversityAI Therapist: Safety and EffectivenessThe author argues that Woebot, an AI therapist, lacks transparency and fails to meet the White House's AI Bill of Rights, citing risks like user complacency and minor consent issues. The piece calls for further clinical trials and human oversight, including psychologist summaries of user conversations, to improve safety and effectiveness.Programming InsiderHow AI Therapy Chatbots Process Emotions Using Large Language ModelsThis article explains how AI therapy chatbots such as Abby, Wysa, and Woebot process emotions using Large Language Models, Natural Language Processing, and evidence-based therapeutic frameworks like Cognitive Behavioral Therapy. A 2025 systematic review of 160 studies found that LLM-based mental health chatbots accounted for nearly 45% of newly studied AI mental health systems by 2024. While research suggests these tools can provide valuable emotional support and improve access to mental health resources, experts note important limitations including struggles with complex trauma, cultural nuance, and subtle mental health cues.JoinphoenixhealthBest Mental Health Apps for Pregnancy & Postpartum (2026)A 2026 guide reviews perinatal mental health apps, noting that Sanvello, Expectful, and Woebot shut down in 2025. It highlights clinically proven apps like Canopie and Baby2Home, and distinguishes OCD from postpartum psychosis. The guide also covers culturally specific and partner-focused options.IwinsMore Employers Offering Wellness, Mental Health ChatbotsA survey by Willis Towers Watson found that 24% of 457 U.S. employers currently offer digital therapeutic apps for mental health support, with another 15% considering adding such offerings in 2024 or 2025. Companies like Amazon are offering therapist-like apps such as Twill, while products like Wysa and Woebot have received FDA breakthrough designation or target specific conditions like postpartum depression. The article notes ongoing controversy, including an $8 million FTC settlement with BetterHelp over data sharing and concerns that these apps are not equipped to handle serious mental health issues.TrendsAI Therapy Apps: Augmentation Play, Crisis Detection, Vertical NichesA market analysis report examines the AI mental health therapy app landscape, noting that ChatGPT has become the largest mental health provider by session volume while specialized apps struggle with retention rates below 3% at 30 days and face liability risks following Character.AI lawsuits involving 7 confirmed user deaths. The report highlights that Spring Health reached a $3.3B valuation through an employer benefits distribution model rather than direct-to-consumer sales, Woebot shut down despite raising $124M and receiving FDA Breakthrough status, and UHS acquired Talkspace for $835M, with analysts noting the behavioral health data was the primary acquisition target. The analysis predicts regulatory tightening will reshape the category, with 15+ states considering AI therapy chatbot restrictions and an FDA-authorized AI mental health solution likely anchoring outside the depression-anxiety axis.openPR.comAI in Mental Health Market (2026-2033) | Early Diagnosis, Chatbots, NLP, Virtual Therapists & Data-Driven Care | Top Companies are Woebot Health, Wysa Ltd, BetterHelp, Lyra Health, IncThe global AI in mental health market reached US$1.95 billion in 2024 and is projected to reach US$12.69 billion by 2033, growing at a CAGR of 22.8% during the forecast period 2025-2033. AI-powered tools such as chatbots, predictive analytics, and natural language processing are being deployed by companies including Woebot Health, Lyra Health, Talkspace, NTT Data, Fujitsu, Sony Group Corporation, and Hitachi to enhance early diagnosis, monitoring, and accessibility of mental health care. The report identifies key market segments by component, technology, application, and end-user, with North America and Asia-Pacific representing significant regional markets.BasicmedicalkeyAI Therapy Apps Compared: 7 Options Tested in 2026This article reviews and compares seven AI therapy apps available in 2026, evaluating them across therapeutic approach, interface type, pricing, and clinical backing. The apps range from free options with strong research support (Woebot with 14 randomized controlled trials) to voice-based alternatives (Lovon at $59.99/year). The piece notes that over 160 million Americans live in mental health professional shortage areas, positioning AI therapy apps as gap-fillers between therapy sessions rather than replacements for licensed care.GetstillmindMeditation statistics 2026: what the data actually showsThis reference article compiles 2026 meditation statistics showing 60.5 million U.S. adults meditated in 2022 (up from 16 million in 2002), with fastest growth among seniors and lower-education groups, and clinical evidence showing MBSR was noninferior to an SSRI for anxiety disorders in a JAMA Psychiatry trial. The article reports that Woebot Health shut down its direct-to-consumer app citing FDA regulatory costs, while Headspace's AI companion Ebb has handled over 7 million messages and the EU AI Act is reshaping app regulation. The meditation app market size estimates vary 48-fold depending on categorization methodology, ranging from $118.8 million to $5.72 billion, and roughly 98 chatbot-specific bills are pending across 34 U.S. states.